Early Differences in Cytokine Production by Severity of Coronavirus Disease 2019

Most patients with coronavirus disease 2019 (COVID-19) experience asymptomatic disease or mild symptoms, but some have critical symptoms requiring intensive care. It is important to determine how patients with asymptomatic or mild COVID-19 react to severe acute respiratory syndrome coronavirus 2 infection and suppress virus spread. Innate immunity is important for evasion from the first virus attack, and it may play an important role in the pathogenesis in these patients. We measured serum cytokine levels in 95 patients with COVID-19 during the infection’s acute phase and report that significantly higher interleukin 12 and 2 levels were induced in patients with asymptomatic or mild disease than in those with moderate or severe disease, indicating the key roles of these cytokines in the pathogenesis of asymptomatic or mild COVID-19.
Interleukin 12 and 2 levels were significantly higher in patients with asymptomatic or mild coronavirus disease 2019 (COVID-19) (acute phase) than in those with moderate or severe disease, indicating the key roles of these cytokines in asymptomatic or mild COVID-19.